Glycaemia management using botanical extracts and supplements
Official title: Evaluation of Two Plant Formulations for the Management of Glycemia on Pre-diabetic Participants
Run by Fytexia · NCT05926947 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if taking certain plant extracts and supplements can help people with high blood sugar levels manage their condition better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 50 Years |
| Sex | All |
| Enrollment | 87 (estimated) |
| Sponsor | Fytexia Industry-sponsored |
| Locations | 1 site (Guadalupe, Murcia) |
| Trial ID | NCT05926947 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are overweight individuals aged 20-50 with fasting plasma glucose levels between 75-125 mg/dL and HbA1c levels between 5-6.5%.
✕Probably not a fit
Patients with metabolic or chronic diseases, menopausal women, or those with a history of obesity and weight loss interventions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a causal relationship between glycemia improvement and the chronic supplementation of polyphenol-rich botanical extracts, white kidney bean extract, chromium picolinate, and zinc bisglycinate. It employs a double-blind, randomized design with three arms, involving 29 volunteers in each arm. The effectiveness of the interventions will be assessed by monitoring changes in HbA1c levels, postprandial glucose, insulin kinetics, and participant questionnaires over the study duration.
Why it matters
Potential benefit: If successful, this study could provide a novel approach to managing glycemia in prediabetic and overweight individuals.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in glycemia management using botanical extracts, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fasting Plasma Glucose 75 - 125 mg/dL * HbA1c: 5.-6.5 % * Both sexes * Overweight BMI range (25-30 Kg/m2) * Age: 20-50 years old Exclusion Criteria: * Metabolic/Chronical disease * Menopausal women * Being pregnant, breastfeeding or wanting to have a baby * Former obese with a history of yoyo effect * Have been involved in a weight loss program in the past 12 months or subjected to weight reduction surgery * Having started or quit smoking, having a high alcohol consumption * Have in the past been in a long-term antibiotherapy (1 month or more) and/or a regular antibiotherapy in the past 12 months * Allergy to olive, blackcurrant, pomegranate, grapefruit, white kidney bean, or corn.
Where it's running
-
UCAM Universidad Católica San Antonio de Murcia
Guadalupe, Murcia, Spain Recruiting
Study contacts
- Principal investigator: Pedro Alcaraz — UCAM (Universidad Catolica San Antonio de Murcia)
- Study coordinator: Julien Cases
- Email: jcases@fytexia.com
- Phone: +33 467219098
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Orforglipron in adults with overweight at risk for obesity-related problems
This study tests whether orforglipron can help people who are overweight and have early signs of metabolic or cardiovascular risk.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Concurrent exercise program changes PCSK9 in adults with overweight
A supervised program of aerobic plus resistance training for eight weeks will test whether it lowers PCSK9 levels in adults who are overweight.
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese
This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.